Alembic Pharmaceuticals Limited (NSE:APLLTD)
India · Delayed Price · Currency is INR 797.00
-5.75 (-0.72%)
Jul 31, 2026, 3:29 PM IST
Alembic Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 73,449 | 66,721 | 62,286 | 56,526 | 53,058 |
Other Revenue | - | -0.1 | - | - | - |
| 73,449 | 66,721 | 62,286 | 56,526 | 53,058 | |
Revenue Growth | 10.08% | 7.12% | 10.19% | 6.54% | -1.62% |
Cost of Revenue | 20,789 | 18,808 | 17,961 | 17,748 | 14,982 |
Gross Profit | 52,660 | 47,912 | 44,325 | 38,778 | 38,076 |
Selling, General & Admin | 17,319 | 15,623 | 14,463 | 11,691 | 11,330 |
Other Operating Expenses | 24,175 | 22,152 | 20,500 | 19,892 | 17,951 |
Operating Expenses | 44,689 | 40,614 | 37,718 | 34,401 | 32,201 |
Operating Income | 7,970 | 7,298 | 6,607 | 4,378 | 5,875 |
Interest Expense | -936.3 | -787.7 | -561.9 | -501.7 | -177.3 |
Interest & Investment Income | 8.6 | 59.6 | 21 | 3.3 | 17.3 |
Earnings From Equity Investments | 2.4 | 8.7 | -9.8 | -309.2 | 52.8 |
Currency Exchange Gain (Loss) | 501.7 | 233.9 | 176.9 | -0.9 | 443.1 |
Other Non Operating Income (Expenses) | 3.5 | 78.3 | 3.9 | 2.4 | 0.5 |
EBT Excluding Unusual Items | 7,550 | 6,891 | 6,238 | 3,572 | 6,211 |
Gain (Loss) on Sale of Investments | 12.3 | 14.7 | 43.9 | 7.5 | 28.7 |
Gain (Loss) on Sale of Assets | 21.7 | 32.6 | 17 | -47 | 5.4 |
Other Unusual Items | -669.9 | - | - | - | - |
Pretax Income | 6,940 | 7,072 | 6,318 | 3,546 | 6,254 |
Income Tax Expense | 231.2 | 1,252 | 160 | 126.1 | 1,045 |
Earnings From Continuing Operations | 6,708 | 5,820 | 6,158 | 3,420 | 5,209 |
Minority Interest in Earnings | 39.4 | 14.1 | - | - | - |
Net Income | 6,748 | 5,834 | 6,158 | 3,420 | 5,209 |
Net Income to Common | 6,748 | 5,834 | 6,158 | 3,420 | 5,209 |
Net Income Growth | 15.66% | -5.26% | 80.07% | -34.35% | -54.56% |
Shares Outstanding (Basic) | 197 | 197 | 197 | 197 | 197 |
Shares Outstanding (Diluted) | 197 | 197 | 197 | 197 | 197 |
Shares Change | - | - | - | - | 1.46% |
EPS (Basic) | 34.33 | 29.68 | 31.33 | 17.40 | 26.50 |
EPS (Diluted) | 34.33 | 29.68 | 31.33 | 17.40 | 26.50 |
EPS Growth | 15.66% | -5.26% | 80.07% | -34.35% | -55.22% |
Free Cash Flow | 3,481 | -4,757 | 4,757 | 2,805 | 1,267 |
Free Cash Flow Per Share | 17.71 | -24.20 | 24.20 | 14.27 | 6.45 |
Dividend Per Share | 12.000 | 11.000 | 11.000 | 8.000 | 10.000 |
Dividend Growth | 9.09% | 0% | 37.50% | -20.00% | -28.57% |
Gross Margin | 71.69% | 71.81% | 71.16% | 68.60% | 71.76% |
Operating Margin | 10.85% | 10.94% | 10.61% | 7.75% | 11.07% |
Profit Margin | 9.19% | 8.74% | 9.89% | 6.05% | 9.82% |
Free Cash Flow Margin | 4.74% | -7.13% | 7.64% | 4.96% | 2.39% |
EBITDA | 10,978 | 9,891 | 9,141 | 6,962 | 8,585 |
EBITDA Margin | 14.95% | 14.82% | 14.67% | 12.32% | 16.18% |
D&A For EBITDA | 3,007 | 2,593 | 2,533 | 2,584 | 2,710 |
EBIT | 7,970 | 7,298 | 6,607 | 4,378 | 5,875 |
EBIT Margin | 10.85% | 10.94% | 10.61% | 7.75% | 11.07% |
Effective Tax Rate | 3.33% | 17.70% | 2.53% | 3.56% | 16.70% |
Revenue as Reported | 73,993 | 67,146 | 62,569 | 56,554 | 53,563 |